Vaccine development is a notoriously challenging career path, given the propensity for negative results. For every 100 potential immunogens made, very few will work. Young scientists often choose research areas more likely to offer career advancement. Hoping in part to address these shortcomings, the International AIDS Vaccine Initiative (IAVI), a global non-profit organization, is investing $30 million to create a new HIV Neutralizing Antibody Center at the Scripps Research Institute in La Jolla, California.
展开▼
